What type of study is this?

This is a In Vitro Study study.

What question did this study set out to answer?

To investigate the effects of high dose ascorbate on innate immune cytokines in chronic myelomonocytic leukemia patients with TET2 mutations.

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Phase 2 trial reduced cytokine levels in chronic myelomonocytic leukemia patients with TET2 mutations, implying ascorbate's therapeutic potential.

To investigate the effects of high dose ascorbate on innate immune cytokines in chronic myelomonocytic leukemia patients with TET2 mutations.
Conducted a phase 2 non-randomized trial with 54 subjects diagnosed with chronic myelomonocytic leukemia.
Patients with TET2 mutations received high dose sodium ascorbate and azacitidine treatment.
Measured vitamin C levels and cytokine profiles at different treatment cycles.
78% of CMML subjects had TET2 mutations, with significant variants detected.
Cytokine levels including IL-1β and IL-13 decreased significantly after treatment, suggesting reduced inflammation.
Vitamin C levels increased notably post-treatment cycles.

Ross et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase 2 trial reduced cytokine levels in chronic myelomonocytic leukemia patients with TET2 mutations, implying ascorbate's therapeutic potential.